Alzamend Neuro (NASDAQ:ALZN) Price Target Cut to $32.00 by Analysts at Ascendiant Capital Markets

Alzamend Neuro (NASDAQ:ALZN) had its price objective reduced by Ascendiant Capital Markets from $35.00 to $32.00 in a report released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Alzamend Neuro Trading Up 2.5 %

ALZN stock opened at $1.22 on Monday. The company has a 50 day simple moving average of $1.45 and a 200 day simple moving average of $2.63. Alzamend Neuro has a 1 year low of $1.06 and a 1 year high of $15.06.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.